Aristotelis Bamias

Athens, ESYE31 12462, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 190 publications

Development and Broad Application of a Double Drop-Off ddPCR Assay for Simultaneous Detection of Four FGFR3 Mutations in Tissue and Liquid Biopsy Samples.

Development and Broad Application of a Double Drop-Off ddPCR Assay for Simultaneous Detection of Four FGFR3 Mutations in Tissue and Liquid Biopsy Samples.

Journal: Cancers

Published: July 14, 2026

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update.

Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update.

Journal: Cancers

Published: April 23, 2026

The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study.

The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study.

Journal: Frontiers in oncology

Published: April 17, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

KIM-1 as a Biomarker in Genitourinary Neoplasms.

KIM-1 as a Biomarker in Genitourinary Neoplasms.

Journal: Cancers

Published: February 15, 2026

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Journal: Frontiers in immunology

Published: February 05, 2026

Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma.

Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma.

Journal: Cancers

Published: January 15, 2026

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Journal: JCO global oncology

Published: July 08, 2025

Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.

Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.

Journal: Molecular oncology

Published: June 29, 2025

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: May 23, 2025

Showing 1-12 of 190

Last Updated: 09/26/2026